| Inferring tumour purity and stromal and immune cell admixture from expression data K Yoshihara, M Shahmoradgoli, E Martínez, R Vegesna, H Kim, ... Nature communications 4 (1), 2612, 2013 | 7286 | 2013 |
| Integrated genomic analyses of ovarian carcinoma Cancer Genome Atlas Research Network Nature 474 (7353), 609, 2011 | 5723 | 2011 |
| Integrated genomic characterization of endometrial carcinoma DA Levine, ... Nature 497 (7447), 67-73, 2013 | 5310 | 2013 |
| The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018 | 5006 | 2018 |
| An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ... Cell 173 (2), 400-416. e11, 2018 | 3064 | 2018 |
| Oncogenic signaling pathways in the cancer genome atlas F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ... Cell 173 (2), 321-337. e10, 2018 | 2828 | 2018 |
| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 2513* | 2020 |
| Comprehensive characterization of cancer driver genes and mutations MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ... Cell 173 (2), 371-385. e18, 2018 | 2425 | 2018 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 2358 | 2017 |
| Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ... Cell 173 (2), 291-304. e6, 2018 | 2272 | 2018 |
| Absolute quantification of somatic DNA alterations in human cancer SL Carter, K Cibulskis, E Helman, A McKenna, H Shen, T Zack, PW Laird, ... Nature biotechnology 30 (5), 413-421, 2012 | 2116 | 2012 |
| Machine learning identifies stemness features associated with oncogenic dedifferentiation TM Malta, A Sokolov, AJ Gentles, T Burzykowski, L Poisson, JN Weinstein, ... Cell 173 (2), 338-354. e15, 2018 | 1846 | 2018 |
| Evaluating cell lines as tumour models by comparison of genomic profiles S Domcke, R Sinha, DA Levine, C Sander, N Schultz Nature communications 4 (1), 2126, 2013 | 1588 | 2013 |
| Rethinking ovarian cancer: recommendations for improving outcomes S Vaughan, JI Coward, RC Bast Jr, A Berchuck, JS Berek, JD Brenton, ... Nature Reviews Cancer 11 (10), 719-725, 2011 | 1573 | 2011 |
| Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria, RC Bast Jr, V Beral, ... Nature reviews Cancer 15 (11), 668-679, 2015 | 1283 | 2015 |
| Resistance to therapy caused by intragenic deletion in BRCA2 SL Edwards, R Brough, CJ Lord, R Natrajan, R Vatcheva, DA Levine, ... Nature 451 (7182), 1111-1115, 2008 | 1142 | 2008 |
| Principles and practice of gynecologic oncology RR Barakat, M Markman, M Randall Lippincott Williams & Wilkins, 2009 | 1024 | 2009 |
| Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas TA Knijnenburg, L Wang, MT Zimmermann, N Chambwe, GF Gao, ... Cell reports 23 (1), 239-254. e6, 2018 | 1012 | 2018 |
| Integrated proteogenomic characterization of human high-grade serous ovarian cancer H Zhang, T Liu, Z Zhang, SH Payne, B Zhang, JE McDermott, JY Zhou, ... Cell 166 (3), 755-765, 2016 | 996 | 2016 |
| Genomic and functional approaches to understanding cancer aneuploidy AM Taylor, J Shih, G Ha, GF Gao, X Zhang, AC Berger, SE Schumacher, ... Cancer cell 33 (4), 676-689. e3, 2018 | 983 | 2018 |
Carol Aghajanian, MDChief, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer CenterZweryfikowany adres z mskcc.org